Myelodysplastic Syndromes News and Research

RSS

myeloMATCH program opens enrollment for acute myeloid leukemia and MDS

Four leading cancer research organizations in the United States and Canada announce the opening of patient enrollment to myeloMATCH, a unique portfolio of clinical trials to test precision medicine treatments for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

23 Oct 2024

NIH launches precision medicine trial to test new treatments for myeloid cancers

The National Institutes of Health (NIH) has launched a proof-of-concept precision medicine clinical trial to test new treatment combinations targeting specific genetic changes in the cancer cells of people with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

23 Oct 2024

Groundbreaking findings on TET2 pathway open doors for targeted blood cancer treatments

Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2).

23 Oct 2024

Breakthrough discovery could boost stem-cell transplants by improving cell mobilization

A discovery by a three-member Albert Einstein College of Medicine research team may boost the effectiveness of stem-cell transplants, commonly used for patients with cancer, blood disorders, or autoimmune diseases caused by defective stem cells, which produce all the body's different blood cells.

8 Aug 2024

Metformin use linked to reduced risk of myeloproliferative neoplasms

People who use metformin are less likely to develop a myeloproliferative neoplasm (MPN) over time, indicating that the treatment may help prevent the development of certain types of cancers, according to a study published in Blood Advances.

17 May 2024

City of Hope cures oldest person of blood cancer and achieves HIV remission

City of Hope, one of the largest cancer research and treatment organizations in the United States, treated the oldest person to be cured of a blood cancer and then achieve remission for HIV after receiving a blood stem cell transplant from a donor with a rare genetic mutation.

15 Feb 2024

Single-cell study reveals clues to epigenetic drug response in Myelodysplastic Syndrome

Researchers from the Josep Carreras Leukaemia Research Institute, spearheaded by the Cancer Epigenetics group led by Dr. Manel Esteller, described the effects of chemotherapy at the single cell resolution in the bone marrow of Myelodysplastic Syndrome patients.

6 Feb 2024

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes (MDS) and other myeloid neoplasms.

11 Dec 2023

MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers

The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia (AML) and other hematologic cancers.

8 Dec 2023

FDA awards grant for phase 1 clinical trial of experimental AML/MDS treatment

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)-;two related blood diseases that disproportionally strike older adults-;are notoriously difficult to treat and associated with high relapse rates.

28 Nov 2023

Scientists uncover "genomic tug of war" that influences chemotherapy's effectiveness

Some patients with myelodysplastic syndromes, like acute myeloid leukemia, benefit from a chemotherapy drug called decitabine that stunts cancer growth. But many others are resistant to decatibine's effects or become resistant over time.

16 Nov 2023

Annual NCCN Congress to focus on latest advances in blood cancer treatment

The National Comprehensive Cancer Network 2023 Annual Congress: Hematologic Malignancies returns to San Francisco this week, for the first time since 2019.

19 Sep 2023

Scientists create new test to identify people at risk of developing myeloid leukemias

Scientists have created a new test for identifying people at risk of developing acute myeloid leukaemia and related cancers, years before they do.

24 Aug 2023

Myelodysplastic syndromes are commonly misdiagnosed, study finds

Blood disorders known as myelodysplastic syndromes/neoplasms (MDS) are difficult to diagnose – and are commonly misdiagnosed – putting patients at increased risk for treatment mistakes and other potentially harmful consequences, according to researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations.

8 Aug 2023

Arima Genomics continues momentum toward clinic with formation of clinical advisory board

Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights to improve human health and drive discovery in the life sciences, today announced the formation of a clinical advisory board to help the company advance its 3D genomics technologies into the clinical oncology and biopharmaceutical markets.

From Arima Genomics, Inc. 5 Jul 2023

Alternative splicing in neurodegenerative disease and the promise of RNA-based therapeutic strategies

Alternative splicing, a clever way a cell generates many different variations of messenger RNAs -; single-stranded RNAs involved in protein synthesis -; and proteins from the same stretch of DNA, plays an important role in molecular biology.

21 Jun 2023

NCI launches new initiative to test new drug combinations that target specific tumor alterations

The National Cancer Institute (NCI) has launched a large precision medicine cancer initiative to test the effectiveness of treating adults and children with new drug combinations that target specific tumor alterations.

1 Jun 2023

Treatment with luspatercept improves red blood cell counts in patients with myelodysplastic syndromes

Treatment with luspatercept improved red blood cell counts and erythroid responses compared to treatment with epoetin alfa in patients with myelodysplastic syndromes (MDS), allowing the majority to no longer require regular blood transfusions.

26 May 2023

Break Through Cancer funds AML research at MD Anderson

The University of Texas MD Anderson Cancer Center was awarded more than $5.7 million in grants from Break Through Cancer to support collaborative research teams working to discover novel molecular targets to eradicate minimal residual disease in acute myeloid leukemia (AML) and to treat clonal hematopoiesis, a precursor to AML.

16 May 2023

Using vitamin B5 supplementation to boost red blood cell production in people with myelodysplastic syndromes

Scientists from Barts Cancer Institute at Queen Mary University of London and the Francis Crick Institute, have uncovered why patients with a rare type of blood cancer suffer from ineffective red blood cell production, and how vitamin B5 could be combined with existing drugs to improve outcomes.

1 Mar 2023

Myelodysplastic Syndromes News and Research

myeloMATCH program opens enrollment for acute myeloid leukemia and MDS

NIH launches precision medicine trial to test new treatments for myeloid cancers

Groundbreaking findings on TET2 pathway open doors for targeted blood cancer treatments

Breakthrough discovery could boost stem-cell transplants by improving cell mobilization

Metformin use linked to reduced risk of myeloproliferative neoplasms

City of Hope cures oldest person of blood cancer and achieves HIV remission

Single-cell study reveals clues to epigenetic drug response in Myelodysplastic Syndrome

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers

FDA awards grant for phase 1 clinical trial of experimental AML/MDS treatment

Scientists uncover "genomic tug of war" that influences chemotherapy's effectiveness

Annual NCCN Congress to focus on latest advances in blood cancer treatment

Scientists create new test to identify people at risk of developing myeloid leukemias

Myelodysplastic syndromes are commonly misdiagnosed, study finds

Arima Genomics continues momentum toward clinic with formation of clinical advisory board

Alternative splicing in neurodegenerative disease and the promise of RNA-based therapeutic strategies

NCI launches new initiative to test new drug combinations that target specific tumor alterations

Treatment with luspatercept improves red blood cell counts in patients with myelodysplastic syndromes

Break Through Cancer funds AML research at MD Anderson

Using vitamin B5 supplementation to boost red blood cell production in people with myelodysplastic syndromes

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News